Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.

PURPOSE Previous studies have linked the use of positron emission tomography (PET) with improved outcomes among patients with non-small-cell lung cancer (NSCLC). However, this association may be confounded by PET-induced stage migration and selection bias. We examined the association between PET use and overall survival among Medicare beneficiaries with NSCLC. PATIENTS AND METHODS Retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) -Medicare data was used to characterize changes in overall survival, stage-specific survival, and stage distribution among Medicare beneficiaries with NSCLC between 1998 and 2003. RESULTS A total of 97,007 patients with NSCLC diagnosed between 1998 and 2003 met the study criteria. Two-year and 4-year survival remained unchanged, despite widespread adoption of PET. The proportion of patients staged with advanced disease increased from 44% to 50%. Upstaging of disease was accompanied by stage-specific improved survival, with 2-year survival of stage IV disease increasing from 8% to 11% between 1998 and 2003. PET was more likely to be administered to patients with less advanced disease (stages I through IIIA) and greater overall survival. CONCLUSION Overall survival among Medicare beneficiaries with NSCLC was unchanged between 1998 and 2003, despite widespread adoption of PET. The association between PET use and increased survival likely reflects an artifact of selection bias and consequent stage migration.

[1]  Harold S. Luft,et al.  Correlation of Travel Time on Roads versus Straight Line Distance , 1995, Medical care research and review : MCRR.

[2]  M. King,et al.  Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[5]  A. Abernethy,et al.  Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. , 2010, JAMA.

[6]  D. Gandara,et al.  Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. , 2008, Archives of internal medicine.

[7]  Beth A Virnig,et al.  Measuring Breast, Colorectal, and Prostate Cancer Screening With Medicare Claims Data , 2002, Medical care.

[8]  J. Warren,et al.  Identifying and Measuring Hospital Characteristics Using the SEER-Medicare Data and Other Claims-Based Sources , 2002, Medical care.

[9]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[10]  Colin B Begg,et al.  Measuring Complications of Cancer Treatment Using the SEER-Medicare Data , 2002, Medical care.

[11]  Gregory S. Cooper,et al.  Studying Radiation Therapy Using SEER-Medicare-Linked Data , 2002, Medical care.

[12]  Y. Ung,et al.  Positron Emission Tomography in Staging Early Lung Cancer , 2009, Annals of Internal Medicine.

[13]  C. Klabunde,et al.  Linking Physician Characteristics and Medicare Claims Data: Issues in Data Availability, Quality, and Measurement , 2002, Medical care.

[14]  P. Heagerty,et al.  Multi-Modality Mediastinal Staging for Lung Cancer Among Medicare Beneficiaries , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  E. Guadagnoli,et al.  Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations , 2002, Medical care.

[16]  Ruth Etzioni,et al.  Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data , 2002, Medical care.

[17]  A. Abernethy,et al.  Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. , 2008, JAMA.

[18]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[19]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[20]  Jean M. Mitchell,et al.  Utilization Trends for Advanced Imaging Procedures: Evidence From Individuals With Private Insurance Coverage in California , 2008, Medical care.

[21]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[22]  J. Sculier.  Nonsmall cell lung cancer , 2013, European Respiratory Review.

[23]  A. Dirksen,et al.  Preoperative staging of lung cancer with combined PET-CT. , 2009, The New England journal of medicine.

[24]  C. Klabunde,et al.  Assessing Comorbidity Using Claims Data: An Overview , 2002, Medical care.

[25]  Kathleen Lang,et al.  Identifying Cancer Relapse Using SEER-Medicare Data , 2002, Medical care.

[26]  J. Subramanian,et al.  Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005 , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[28]  G. Cooper,et al.  Use of SEER-Medicare Data for Measuring Cancer Surgery , 2002, Medical care.